J&J CFO on Third-Quarter, Outlook, Consumer Spinoff

The transcript covers a discussion on the impact of a strong dollar on company growth, economic conditions, and inflation. It highlights the company's strategies to manage inflation and input costs, updates on the consumer spinoff, and future plans for Johnson & Johnson. The conversation also touches on the strategy for pharmaceuticals and Med tech growth, and insights into the COVID vaccine demand.

What was the company's growth rate outside the U.S. in the third quarter?

• 4%

• 16%

• 12%

• 8%

How does the company view its resilience during economic downturns?

• More resilient than most industries

• Less resilient than most industries

• Equally resilient as other industries

• Not resilient at all

What is the company's strategy regarding input costs and inflation?

• Reduce production to cut costs

• Absorb the extra costs and hope for future alleviation

• Pass all costs to consumers

• Ignore the rising costs

What is the name of the new consumer health company?

• PharmaView

• MedView

• KANVIEW

• HealthView

What is the company's approach to strengthening its pharmaceutical and Med tech areas?

• Reducing investments

• Focusing solely on existing products

• Strategic acquisitions and deals

• Discontinuing less profitable products

How much cash does the company have for strategic acquisitions?

• $13 billion

• $24 billion

• $34 billion

• $44 billion

What is the company's stance on the COVID vaccine business?

• Discontinuing the vaccine

• Expanding production significantly

• It is a major financial driver

• Focus on fulfilling existing commitments